Brokerages Expect Tetraphase Pharmaceuticals Inc. (TTPH) to Post -$0.41 Earnings Per Share

Wall Street brokerages expect Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) to report earnings per share of ($0.41) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from ($0.47) to ($0.33). Tetraphase Pharmaceuticals reported earnings per share of ($0.79) in the same quarter last year, which would indicate a positive year over year growth rate of 48.1%. The business is expected to issue its next quarterly earnings report on Thursday, May 3rd.

According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($1.58) per share for the current year, with EPS estimates ranging from ($1.86) to ($1.21). For the next financial year, analysts anticipate that the company will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.82) to ($0.96). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.18. Tetraphase Pharmaceuticals had a negative return on equity of 90.75% and a negative net margin of 1,187.17%. The business had revenue of $2.53 million during the quarter, compared to analyst estimates of $2.26 million.

Several brokerages have recently commented on TTPH. BMO Capital Markets restated a “market perform” rating and issued a $3.00 price objective (up from $2.75) on shares of Tetraphase Pharmaceuticals in a research report on Thursday, March 8th. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, March 7th. HC Wainwright lowered their price objective on Tetraphase Pharmaceuticals from $17.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, February 14th. BidaskClub downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, WBB Securities began coverage on Tetraphase Pharmaceuticals in a research report on Thursday, February 22nd. They issued a “speculative buy” rating and a $6.00 price objective on the stock. Two analysts have rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $7.22.

Shares of Tetraphase Pharmaceuticals stock opened at $3.18 on Wednesday. Tetraphase Pharmaceuticals has a 52 week low of $2.05 and a 52 week high of $8.75. The stock has a market capitalization of $158.91, a PE ratio of -1.21 and a beta of 2.61.

In other news, insider Jacques Dumas sold 8,750 shares of the business’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total value of $54,425.00. Following the transaction, the insider now directly owns 8,750 shares in the company, valued at $54,425. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in shares of Tetraphase Pharmaceuticals in the third quarter worth about $107,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Tetraphase Pharmaceuticals in the third quarter worth about $195,000. Paloma Partners Management Co purchased a new stake in shares of Tetraphase Pharmaceuticals in the fourth quarter worth about $210,000. American International Group Inc. lifted its position in shares of Tetraphase Pharmaceuticals by 44.1% in the third quarter. American International Group Inc. now owns 33,826 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 10,345 shares in the last quarter. Finally, Virtus Fund Advisers LLC purchased a new stake in shares of Tetraphase Pharmaceuticals in the fourth quarter worth about $376,000. Institutional investors own 58.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply